Menu
Search
|

Menu

Close
X

Proteon Therapeutics Inc PRTO.OQ (NASDAQ Stock Exchange Global Market)

0.43 USD
-0.00 (-0.70%)
As of 4:00 PM EDT
Previous Close 0.43
Open 0.43
Volume 55,346
3m Avg Volume 246,760
Today’s High 0.44
Today’s Low 0.42
52 Week High 3.88
52 Week Low 0.35
Shares Outstanding (mil) 19.59
Market Capitalization (mil) 8.44
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.00 Mean rating from 2 analysts

KEY STATS

Revenue (mm, USD)
FY19
0
FY18
0
FY17
0
FY16
0
EPS (USD)
FY19
-0.339
FY18
-1.147
FY17
-2.116
FY16
-1.722
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.23
Price to Sales (TTM)
vs sector
--
10.86
Price to Book (MRQ)
vs sector
--
4.40
Price to Cash Flow (TTM)
vs sector
--
24.08
Total Debt to Equity (MRQ)
vs sector
0.00
18.12
LT Debt to Equity (MRQ)
vs sector
0.00
12.99
Return on Investment (TTM)
vs sector
-95.88
12.65
Return on Equity (TTM)
vs sector
-2,875.63
17.19

EXECUTIVE LEADERSHIP

Timothy Noyes
President, Chief Executive Officer, Director, Since 2006
Salary: $501,806.00
Bonus: --
George Eldridge
Chief Financial Officer, Senior Vice President, Treasurer, Assistant Secretary,, Since 2013
Salary: $352,690.00
Bonus: --
E. Scott Toner
Senior Vice President - Marketing, Since 2015
Salary: --
Bonus: --
Steven Burke
Senior Vice President, Chief Medical Officer, Since 2006
Salary: $420,240.00
Bonus: --
Matthew Kowalsky
Vice President, Legal and Secretary, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

200 West St
WALTHAM   MA   02451-1121

Phone: +1781.8900102

Proteon Therapeutics, Inc. is a late-stage biopharmaceutical company. The Company is focused on the development of pharmaceuticals to address patients with renal and vascular disease. The Company’s product candidate, vonapanitase, is a recombinant human elastase. The Company is developing vonapanitase to improve vascular access outcomes in patients with chronic kidney disease (CKD), undergoing or planning for hemodialysis.

SPONSORED STORIES